ORBIMED ADVISORS LLC
Reported holdings as of Q2 2026, from 31 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| EDGEWISE THERAPEUTICS INC | EWTX | $630.5M | 15,518,492 | +1.95pp | 22q | HELD | |
| ENLIVEN THERAPEUTICS INC | ELVN | $343.9M | 6,776,632 | +0.16pp | 14q | -14.9%-$60.0M | |
| ELI LILLY & CO | LLY | $309.3M | 257,900 | +1.40pp | 14q | +8.9%+$25.3M | |
| MBX BIOSCIENCES INC | MBX | $189.3M | 3,428,736 | +1.35pp | 8q | -5.7%-$11.5M | |
| SINOVAC BIOTECH LTD | SVA | $184.5M | 2,718,735 | -0.25pp | 17q | HELD | |
| ASTRAZENECA PLC | AZN | $171.1M | 915,700 | +0.54pp | 2q | +36.6%+$45.9M | |
| STRUCTURE THERAPEUTICS INC | GPCR | $118.6M | 2,209,400 | +0.78pp | 9q | +49.7%+$39.4M | |
| SIONNA THERAPEUTICS INC | SION | $112.4M | 2,555,877 | -0.73pp | 6q | -27.6%-$42.9M | |
| CORVUS PHARMACEUTICALS INC | CRVS | $107.0M | 7,165,006 | -0.10pp | 31q | HELD | |
| ARRIVENT BIOPHARMA INC | AVBP | $105.2M | 3,027,328 | +0.56pp | 10q | HELD | |
| ABIVAX SA OPT | ABVX | $99.5M | 546,522 | +0.81pp | 4q | +17.4%+$14.7M | |
| GUARDANT HEALTH INC | GH | $87.6M | 583,700 | +0.82pp | 2q | +34.1%+$22.3M | |
| ARGENX SE | ARGX | $86.2M | 92,880 | -0.39pp | 18q | -32.2%-$40.8M | |
| MERCK & CO INC | MRK | $85.2M | 663,400 | -0.01pp | 2q | HELD | |
| UNIQURE NV | QURE | $83.3M | 1,807,486 | +0.85pp | 4q | -15.4%-$15.1M | |
| PRAXIS PRECISION MEDICINES I | PRAX | $77.0M | 230,100 | +0.32pp | 3q | +33.4%+$19.3M | |
| EDWARDS LIFESCIENCES CORP | EW | $75.5M | 834,900 | -0.56pp | 7q | -32.2%-$35.8M | |
| PRELUDE THERAPEUTICS INC | PRLD | $73.2M | 13,724,571 | +0.61pp | 24q | +25.8%+$15.0M | |
| DYNE THERAPEUTICS INC | DYN | $71.9M | 3,235,684 | +0.28pp | 10q | +10.9%+$7.1M | |
| NATERA INC | NTRA | $71.1M | 262,000 | +0.27pp | 31q | HELD | |
| UNITEDHEALTH GROUP INC OPT | UNH | $71.1M | 161,100 | - | new | NEW | |
| CG ONCOLOGY INC | CGON | $69.1M | 972,800 | flat | 8q | +2.6%+$1.7M | |
| ARS PHARMACEUTICALS INC | SPRY | $66.4M | 8,288,510 | -0.09pp | 23q | HELD | |
| ASCENDIS PHARMA A/S | ASND | $65.2M | 244,456 | - | new | NEW | |
| HUMANA INC | HUM | $65.2M | 164,100 | - | new | NEW | |
| COGENT BIOSCIENCES INC | COGT | $65.1M | 1,681,300 | +0.96pp | 3q | +422.0%+$52.6M | |
| BOSTON SCIENTIFIC CORP | BSX | $63.3M | 1,483,200 | -1.80pp | 31q | -37.7%-$38.4M | |
| INTUITIVE SURGICAL INC | ISRG | $62.8M | 157,900 | -0.75pp | 31q | -24.3%-$20.2M | |
| MINERALYS THERAPEUTICS INC | MLYS | $56.9M | 2,110,300 | -0.05pp | 5q | +2.8%+$1.5M | |
| ODYSSEY THERAPEUTICS INC | ODTX | $56.2M | 3,001,198 | - | new | NEW | |
| XENON PHARMACEUTICALS INC | XENE | $53.9M | 892,471 | -0.23pp | 31q | -15.8%-$10.1M | |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | $53.5M | 2,042,000 | - | new | NEW | |
| BRISTOL-MYERS SQUIBB CO | BMY | $53.3M | 925,000 | -0.13pp | 3q | HELD | |
| Q32 BIO INC | QTTB | $52.6M | 4,127,987 | +0.69pp | 10q | +83.2%+$23.9M | |
| PALVELLA THERAPEUTICS INC NE OPT | PVLA | $50.8M | 292,360 | +0.48pp | 2q | +117.2%+$27.4M | |
| STRYKER CORPORATION | SYK | $50.1M | 159,100 | -0.27pp | 24q | -12.8%-$7.4M | |
| CARIS LIFE SCIENCES INC | CAI | $50.0M | 2,806,811 | -0.07pp | 5q | HELD | |
| ELEVANCE HEALTH INC FORMERLY OPT | ELV | $48.2M | 114,700 | +0.23pp | 3q | HELD | |
| SPDR SERIES TRUST OPT | XBI | $47.5M | options only | - | new | OPTIONS | |
| THERMO FISHER SCIENTIFIC INC | TMO | $45.5M | 90,700 | +0.39pp | 31q | +95.1%+$22.2M | |
| SHATTUCK LABS INC | STTK | $43.8M | 6,306,127 | flat | 4q | HELD | |
| UPSTREAM BIO INC | UPB | $39.4M | 5,693,589 | -0.29pp | 7q | HELD | |
| CRINETICS PHARMACEUTICALS IN | CRNX | $37.4M | 999,000 | -0.03pp | 31q | HELD | |
| RHYTHM PHARMACEUTICALS INC | RYTM | $35.9M | 322,900 | +0.12pp | 12q | +2.8%+$977.1K | |
| SYNDAX PHARMACEUTICALS INC | SNDX | $33.7M | 1,542,000 | +0.18pp | 2q | +60.2%+$12.7M | |
| FORTE BIOSCIENCES INC | FBRX | $33.5M | 1,577,705 | flat | 7q | +31.8%+$8.1M | |
| COMPASS THERAPEUTICS INC | CMPX | $33.3M | 15,219,994 | -0.99pp | 19q | HELD | |
| NEKTAR THERAPEUTICS | NKTR | $32.5M | 465,346 | +0.21pp | 2q | +69.2%+$13.3M | |
| KRYSTAL BIOTECH INC | KRYS | $30.9M | 83,200 | +0.22pp | 11q | +20.4%+$5.2M | |
| 000000000 | $30.3M | 5,680,186 | - | new | NEW | ||
| AXSOME THERAPEUTICS INC | AXSM | $28.8M | 117,578 | -0.19pp | 6q | -45.0%-$23.6M | |
| KINIKSA PHARMACEUTICALS INTL | KNSA | $26.9M | 420,600 | +0.33pp | 3q | +132.9%+$15.3M | |
| TREVI THERAPEUTICS INC | TRVI | $26.7M | 1,430,293 | -0.09pp | 6q | -41.7%-$19.1M | |
| DISC MEDICINE INC | IRON | $26.2M | 357,535 | -0.87pp | 15q | -66.5%-$51.9M | |
| WEST PHARMACEUTICAL SVSC INC | WST | $25.3M | 70,600 | - | new | NEW | |
| RELMADA THERAPEUTICS INC | RLMD | $25.1M | 3,631,195 | -0.19pp | 3q | -23.0%-$7.5M | |
| UROGEN PHARMA LTD | URGN | $24.9M | 676,187 | +0.15pp | 5q | -22.8%-$7.3M | |
| SUTRO BIOPHARMA INC | STRO | $24.7M | 743,944 | +0.06pp | 2q | -7.1%-$1.9M | |
| SAVARA INC | SVRA | $24.4M | 3,959,900 | +0.38pp | 2q | +523.6%+$20.5M | |
| NEUROPACE INC | NPCE | $23.9M | 1,505,125 | -0.11pp | 21q | -28.2%-$9.4M | |
| AURA BIOSCIENCES INC | AURA | $23.7M | 3,333,333 | - | new | NEW | |
| PROTAGONIST THERAPEUTICS INC OPT | PTGX | $23.5M | 42,100 | +0.35pp | 3q | HELD | |
| REVOLUTION MEDICINES INC OPT | RVMD | $22.6M | 70,500 | +0.32pp | 3q | +35.6%+$5.9M | |
| ORIC PHARMACEUTICALS INC | ORIC | $21.8M | 2,015,000 | -0.28pp | 6q | -25.2%-$7.4M | |
| CYBIN INC | HELP | $21.6M | 3,271,400 | +0.03pp | 3q | -14.6%-$3.7M | |
| BIOCRYST PHARMACEUTICALS INC | BCRX | $18.5M | 1,852,000 | +0.07pp | 4q | +29.9%+$4.3M | |
| BIOAGE LABS INC | BIOA | $18.4M | 752,153 | +0.09pp | 8q | +5.7%+$988.8K | |
| LEXEO THERAPEUTICS INC | LXEO | $18.4M | 3,947,850 | -0.07pp | 3q | +9.6%+$1.6M | |
| WHITEHAWK THERAPEUTICS INC | WHWK | $18.0M | 3,934,296 | +0.05pp | 6q | -5.6%-$1.1M | |
| DEFINIUM THERAPEUTICS INC | DFTX | $17.2M | 365,400 | +0.02pp | 2q | -54.6%-$20.6M | |
| SPYRE THERAPEUTICS INC | SYRE | $16.5M | 186,145 | - | new | NEW | |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | $16.3M | 1,737,287 | -0.02pp | 8q | HELD | |
| VERA THERAPEUTICS INC | VERA | $15.9M | 369,596 | flat | 3q | HELD | |
| ALUMIS INC | ALMS | $15.4M | 548,163 | +0.05pp | 5q | HELD | |
| EYEPOINT INC | EYPT | $15.3M | 1,069,147 | +0.01pp | 4q | HELD | |
| WATERS CORP | WAT | $15.1M | 40,300 | - | new | NEW | |
| MONOPAR THERAPEUTICS INC | MNPR | $14.6M | 157,423 | - | new | NEW | |
| TRAVERE THERAPEUTICS INC | TVTX | $14.4M | 253,000 | - | new | NEW | |
| TAYSHA GENE THERAPIES INC | TSHA | $13.6M | 2,000,000 | - | new | NEW | |
| BIOGEN INC | BIIB | $13.3M | 61,600 | +0.02pp | 2q | HELD | |
| DIANTHUS THERAPEUTICS INC | DNTH | $11.2M | 115,000 | - | new | NEW | |
| SPRUCE BIOSCIENCES INC | SPRB | $10.8M | 200,000 | - | new | NEW | |
| LIFESTANCE HEALTH GROUP INC | LFST | $10.1M | 947,400 | +0.12pp | 2q | +89.5%+$4.8M | |
| ERASCA INC | ERAS | $9.1M | 495,900 | - | new | NEW | |
| PROTARA THERAPEUTICS INC | TARA | $8.5M | 2,220,000 | - | new | NEW | |
| KEROS THERAPEUTICS INC | KROS | $8.1M | 759,155 | -0.02pp | 25q | HELD | |
| JANUX THERAPEUTICS INC | JANX | $8.1M | 524,700 | -0.12pp | 21q | -46.7%-$7.0M | |
| TECTONIC THERAPEUTIC INC | TECX | $7.8M | 226,600 | flat | 3q | HELD | |
| ADICET BIO INC | ACET | $7.3M | 844,787 | flat | 3q | -17.8%-$1.6M | |
| PHARVARIS N V | PHVS | $7.1M | 205,400 | +0.02pp | 3q | HELD | |
| ALTO NEUROSCIENCE INC | ANRO | $6.8M | 257,852 | +0.05pp | 7q | +53.9%+$2.4M | |
| ZENTALIS PHARMACEUTICALS INC | ZNTL | $6.7M | 1,390,576 | - | new | NEW | |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | $6.5M | 93,000 | +0.06pp | 2q | +132.5%+$3.7M | |
| ALX ONCOLOGY HLDGS INC | ALXO | $5.9M | 2,866,256 | flat | 2q | HELD | |
| TRAVERE THERAPEUTICS INC | $5.9M | 5,000,000 | - | new | DEBT | ||
| XILIO THERAPEUTICS INC | XLO | $5.7M | 592,300 | - | new | NEW | |
| BICARA THERAPEUTICS INC | BCAX | $5.7M | 191,100 | -0.16pp | 3q | -71.4%-$14.1M | |
| IMAGENEBIO INC | IMA | $5.4M | 909,269 | +0.06pp | 4q | +140.2%+$3.1M | |
| ALNYLAM PHARMACEUTICALS INC | ALNY | $5.1M | 17,000 | -0.69pp | 9q | -85.7%-$30.7M | |
| PALISADE BIO INC | PALI | $4.9M | 2,333,000 | +0.01pp | 3q | HELD | |
| REVOLUTION MEDICINES INC | $4.4M | 3,500,000 | - | new | DEBT | ||
| ATAIBECKLEY INC | ATAI | $4.2M | 797,500 | +0.05pp | 2q | +129.8%+$2.4M | |
| PTC THERAPEUTICS INC | PTCT | $4.0M | 49,100 | +0.01pp | 3q | HELD | |
| ARTIVION INC | AORT | $3.9M | 175,000 | -0.04pp | 2q | +15.9%+$539.3K | |
| NEUMORA THERAPEUTICS INC. | NMRA | $3.6M | 2,139,882 | - | new | NEW | |
| ACADIA PHARMACEUTICALS INC | ACAD | $3.5M | 137,000 | - | new | NEW | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $3.3M | 183,400 | - | new | NEW | |
| TYRA BIOSCIENCES INC | TYRA | $3.3M | 102,000 | - | new | NEW | |
| RAPPORT THERAPEUTICS INC | RAPP | $3.2M | 76,616 | - | new | NEW | |
| AGOMAB THERAPEUTICS NV | AGMB | $2.5M | 192,740 | - | new | NEW | |
| TARSUS PHARMACEUTICALS INC | TARS | $2.2M | 35,581 | - | new | NEW | |
| ACLARIS THERAPEUTICS INC | ACRS | $2.2M | 421,500 | - | new | NEW | |
| CYTOKINETICS INC | CYTK | $2.2M | 25,800 | - | new | NEW | |
| INSPIREMD INC | NSPR | $2.2M | 3,133,405 | -0.06pp | 13q | HELD | |
| OCULAR THERAPEUTIX INC | OCUL | $2.2M | 220,000 | - | new | NEW | |
| EVOMMUNE INC | EVMN | $2.1M | 161,000 | - | new | NEW | |
| BELITE BIO INC | BLTE | $2.0M | 13,300 | - | new | NEW | |
| OVID THERAPEUTICS INC | OVID | $2.0M | 747,000 | - | new | NEW | |
| EUPRAXIA PHARMACEUTICALS INC | EPRX | $1.8M | 269,000 | - | new | NEW | |
| SELLAS LIFE SCIENCES GROUP I OPT | SLS | $1.4M | options only | - | new | OPTIONS | |
| COGENT BIOSCIENCES INC | $1.2M | 1,000,000 | flat | 3q | DEBT | ||
| VIRIDIAN THERAPEUTICS INC | $1.1M | 1,000,000 | - | new | DEBT | ||
| TRAWS PHARMA INC | TRAW | $1.0M | 1,203,260 | flat | 8q | +98.7%+$504.1K |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $4.3B | 82.7% |
| Medical Devices | $307.1M | 5.9% |
| Healthcare Services | $218.9M | 4.2% |
| Insurance | $184.5M | 3.5% |
| Other sectors | $45.5M | 0.9% |
| Not classified | $146.5M | 2.8% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $5.4B | 123 | 38 | 32 | 25 | 24 | 42.1% | 45 |
| Q1 2026 | $5.0B | 109 | 26 | 24 | 33 | 21 | 44.4% | 45 |
| Q4 2025 | $4.9B | 104 | 23 | 21 | 34 | 22 | 40.8% | 48 |
| Q3 2025 | $4.2B | 103 | 23 | 13 | 22 | 18 | 41.1% | 45 |
| Q2 2025 | $4.0B | 98 | 16 | 19 | 23 | 24 | 49.1% | 45 |
| Q1 2025 | $4.2B | 106 | 10 | 15 | 22 | 15 | 47.9% | 45 |
| Q4 2024 | $4.8B | 111 | 20 | 23 | 21 | 21 | 44.4% | 45 |
| Q3 2024 | $5.5B | 112 | 21 | 19 | 30 | 18 | 41.8% | 45 |
| Q2 2024 | $5.0B | 109 | 12 | 21 | 20 | 14 | 44.2% | 45 |
| Q1 2024 | $5.4B | 111 | 20 | 22 | 29 | 18 | 39.2% | 45 |
| Q4 2023 | $5.0B | 109 | 14 | 17 | 26 | 26 | 36.7% | 45 |
| Q3 2023 | $4.7B | 121 | 18 | 15 | 23 | 17 | 33.3% | 45 |
| Q2 2023 | $5.5B | 120 | 17 | 23 | 28 | 12 | 33.6% | 45 |
| Q1 2023 | $5.0B | 115 | 18 | 24 | 29 | 17 | 35.7% | 45 |
| Q4 2022 | $5.2B | 114 | 9 | 25 | 20 | 23 | 35.0% | 45 |
| Q3 2022 | $5.3B | 128 | 14 | 30 | 29 | 24 | 31.0% | 45 |
| Q2 2022 | $5.5B | 138 | 12 | 25 | 35 | 14 | 32.5% | 46 |
| Q1 2022 | $6.1B | 140 | 11 | 32 | 26 | 28 | 32.7% | 46 |
| Q4 2021 | $7.6B | 157 | 13 | 33 | 43 | 25 | 29.6% | 45 |
| Q3 2021 | $8.8B | 169 | 29 | 28 | 25 | 16 | 30.6% | 46 |
| Q2 2021 | $9.6B | 156 | 25 | 24 | 24 | 23 | 31.2% | 47 |
| Q1 2021 | $10.3B | 154 | 35 | 39 | 24 | 29 | 32.9% | 47 |
| Q4 2020 | $11.4B | 148 | 26 | 27 | 19 | 19 | 37.6% | 47 |
| Q3 2020 | $8.0B | 141 | 29 | 20 | 24 | 20 | 33.8% | 47 |
| Q2 2020 | $7.1B | 132 | 23 | 28 | 27 | 31 | 31.3% | 45 |
| Q1 2020 | $6.0B | 140 | 34 | 33 | 28 | 29 | 34.2% | 45 |
| Q4 2019 | $7.0B | 135 | 39 | 17 | 32 | 17 | 37.6% | 45 |
| Q3 2019 | $5.3B | 113 | 18 | 17 | 35 | 28 | 38.7% | 45 |
| Q2 2019 | $6.5B | 123 | 20 | 26 | 20 | 16 | 39.4% | 45 |
| Q1 2019 | $6.5B | 119 | 21 | 25 | 25 | 29 | 40.0% | 45 |
| Q4 2018 | $5.4B | 127 | 0 | 0 | 0 | 0 | 37.6% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.